Drug-Eluting Stents Market Devices

1. DelveInsight launched a new report “Drug-Eluting Stents - Market Insights, Competitive Landscape and Market Forecast–2026”. The Drug-Eluting Stents market report delivers an in-depth understanding of Drug-Eluting Stents and the historical and forecasted Drug-Eluting Stents market trends in the US, EU5 (Germany, France, Spain, Italy, and the United Kingdom) and Japan. Stents are small, expandable tubes inserted after percutaneous coronary intervention (PCI) to keep the arteries open and improve the blood flow. In general, stents are classified into two: bare metal stents and drug eluting stents. • Bare metal stents- these stents are devoid of special coating. They are used as scaffold to properly open the arteries after they are widened with angioplasty. With the course of time, as the artery heals tissue grows around the stent, holding it in place. However, overgrowth of the tissue can lead to re-blockage. • Drug-eluting stents- these stents are coated with medicines which slowly elute to prevent the overgrowth of scar tissue in artery lining. Earlier the drug eluting stents were made of stainless steel and were coarse. Currently, new generation drug eluting stents are in more use as they are made of different kinds of alloys, such as cobalt chromium or platinum chromium, are thinner, have high radial strength and radiopacity, and enhance biocompatibility as well as corrosion resistance. The Drug-Eluting Stents market report provides an overview of Drug-Eluting Stents, applications of Drug-Eluting Stents as well as its PEST Analysis. Additionally, the report provides insight on the Drug-Eluting Stents market share of the individual Drug-Eluting Stents, current and forecasted Drug-Eluting Stents market size from 2018 to 2026 segmented by seven major markets. The Drug-Eluting Stents report also covers the market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.

2. Request for a free sample copy of our report. Drug-Eluting Stents Overview Stents are small, expandable tubes inserted after percutaneous coronary intervention (PCI) to keep the arteries open and improve the blood flow. In general, stents are classified into two: bare metal stents and drug eluting stents. Earlier the drug eluting stents were made of stainless steel and were coarse. Currently, new generation drug eluting stents are in more use as they are made of different kinds of alloys, such as cobalt chromium or platinum chromium, are thinner, have high radial strength and radiopacity, and enhance biocompatibility as well as corrosion resistance. Geographies covered in Drug-Eluting Stents market report: The US, EU5 (Germany, France, Spain, Italy, and the United Kingdom), and Japan Drug-Eluting Stents Key Pharma Players: Key pharma players involved in the development of Drug-Eluting Stents Devices are: 1. Abbott 2. Braun Melsungen AG 3. Biosensors International Group, Ltd 4. BIOTRONIK SE & Co. KG 5. Boston Scientific Corporation 6. Terumo Corporation 7. Medtronic 8. MicroPort Scientific Corporation 9. STENTYS SA Drug-Eluting Stents Market Segmentation 1. By Product Type   Coronary stent Peripheral stent 2. By Scaffold    Cobalt-chromium alloy Nitinol Others 3. By End-User   Hospitals Specialty Clinics Drug-Eluting Stents Market Dynamics

3. Market Drivers   Rising demand for minimally invasive procedures Shifting preferences towards drug-eluting stents over angioplasty Market Barriers  Risk associated with the stents Drug Eluting Stents Market Insights According to the market research study by DelveInsight, the drug-eluting stents market in 7MM is estimated to be XX million in 2026. The overall market size for drug-eluting stents in the United States is anticipated to rise from XX million in 2018 and reach up to XX million by 2026, growing at a CAGR of XX%. The total market size of the drug-eluting stents market are segmented according to type which include coronary stent and peripheral stent. Based on scaffold the drug-eluting stents market is categorized into Cobalt-chromium alloy, nitinol, and others. The major end-users for drug- eluting stents are hospitals, and specialty clinics. The United State market across 7MM is estimated to contribute maximum share of XX%, followed by EU5 with XX%. Growing burden of old age population coupled with sedentary lifestyle is likely to increase the prevalence for atherosclerosis thus, fueling the market. Shifting preferences to drug eluting stents over angioplasty is anticipated to augment the market. Moreover, demand for minimally-invasive procedures is also a driving factor. However, risk associated with the stents such as thrombosis and endothelia tissue disruption is likely to hinder the market. Drug-Eluting Stents Market Landscape The market is segmented by type, scaffold and end user. It has wide usage across the 7MM and presence of major players in the market such as Boston Scientific Corporation, Abbott, among others. The market is consolidated with many devices as angioplasty for blocked arteries is a common surgery. The market is expected to be driven by the factors such as technological advancement in drug-eluting stents, rising demand for minimally invasive surgery procedures, and growing burden of old age population with increase chances of developing blocked arteries owing to sedentary lifestyle. However, risk associated with the stents is likely to hamper the market growth. The overall market size for Drug-Eluting Stents in the United State is anticipated to rise from XX million in 2018 and reach up to XX million by 2026, growing at a CAGR of XX%. To know more, visit @Drug-Eluting Stents Market Landscape